This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Hereditary hypogammaglobulinaemia유전성 저감마글로불린혈증

ICD-10: D80.0 | Synonyms: familial hypogammaglobulinemia, Familial hypogammaglobulinaemia, congenital hypogammaglobulinemia

Contents
  1. History
  2. Causes
  3. Genetics
  4. General epidemiology
  5. Pathophysiology
  6. Symptoms
  7. Signs
  8. Screening
  9. Diagnosis
  10. Treatment
  11. Prognosis
  12. Prevention
  13. References

1. History

Establishment of the concept of hypogammaglobulinemia

The history of immunoglobulin deficiency diseases begins with Bruton's description of agammaglobulinemia in 1952. Subsequently, a group of hereditary diseases showing hypogammaglobulinemia (markedly decreased but with some remaining), milder than agammaglobulinemia, began to be classified separately. With the introduction of immunoelectrophoresis and immunodiffusion in the 1960s–1970s, various immunoglobulin deficiency phenotypes could be evaluated quantitatively.

Classification of hereditary hypogammaglobulinemia

Hereditary hypogammaglobulinemia is not a single disease but a heterogeneous group of diseases caused by multiple genetic causes. As various gene variants were identified as causes over the 1980s–1990s, congenital/hereditary hypogammaglobulinemia was established as a separate disease classification system.

Discovery of causative molecules

From the 1990s to the 2010s, various genes involved in B cells and antibody production, such as NFKB1, NFKB2, CARD11, PIK3CD, PIK3R1, LRBA, CTLA4, were discovered as causes of hereditary hypogammaglobulinemia. This contributed to understanding the complex molecular network of B cell development and maintenance of function.

Recognition in Korea

In Korea, as awareness of primary immunodeficiency diseases increased, diagnosed cases of hereditary hypogammaglobulinemia began to be reported from the late 1990s. It is currently registered as a rare disease, and improvements in genetic diagnosis and access to specialized immunology clinics are continuing.

2. Causes

Diverse genetic causes

Hereditary hypogammaglobulinemia is caused by abnormalities in various genes involved in B cell development, function, or antibody secretion. It includes not only blockage of B cell development itself but also cases in which B cells are present but functional differentiation or antibody production capacity is reduced, resulting in hypogammaglobulinemia.

NFKB1 and NFKB2 variants

NFKB1 (NF-κB p50) and NFKB2 (NF-κB p52) proteins are transcription factors essential for immune cell development and survival. Heterozygous variants of NFKB1 mainly cause a common variable immunodeficiency (CVID)-like phenotype, and NFKB2 variants are sometimes accompanied by hypogammaglobulinemia and hypopituitarism.

CARD11 and LRBA variants

Loss-of-function variants of the CARD11 gene impair NF-κB signaling in B cells and T cells, causing hypogammaglobulinemia. Deficiency of the LRBA (LPS-responsive beige-like anchor protein) gene causes impaired recycling of CTLA-4, resulting in a phenotype combining autoimmunity and immunodeficiency.

PIK3CD gain-of-function variants

PI3Kδ overactivation (activated PI3K delta syndrome, APDS) is caused by gain-of-function variants of PIK3CD and results in abnormal B cell maturation and hypogammaglobulinemia.

3. Genetics

Diverse inheritance patterns

Hereditary hypogammaglobulinemia has different modes of inheritance depending on the causative gene. Various modes of inheritance exist, including autosomal dominant inheritance (NFKB1, NFKB2, CARD11 loss of function, PIK3CD gain of function, CTLA4), autosomal recessive inheritance (LRBA, ICOS, CD81, etc.), and X-linked recessive inheritance (XLA due to BTK variants).

Incomplete penetrance and variable phenotype

Autosomal dominant forms (e.g., NFKB1 heterozygous variants) are characterized by incomplete penetrance and variable expressivity, with phenotypes varying even within the same family. Some carriers show normal immune function, while others show mild to severe hypogammaglobulinemia.

Sporadic variants

In some patients, the disease arises from de novo variants without a family history, and CARD11 and PIK3CD gain-of-function variants have been reported to occur de novo.

4. General epidemiology

Incidence

The exact incidence of hereditary hypogammaglobulinemia varies greatly by causative gene, and overall it is a rare disease. NFKB1 heterozygous variants may show a prevalence similar to that of common variable immunodeficiency (1/25,000–1/50,000).

Age at diagnosis and sex distribution

Depending on the causative gene and mode of inheritance, it is diagnosed at various ages, including childhood, adolescence, and adulthood. When the mode of inheritance is autosomal, both men and women can be affected.

Status in Korea

In Korea, systematic epidemiological studies of hereditary hypogammaglobulinemia among primary immunodeficiency diseases are lacking, but with the Korean primary immunodeficiency registry program and the introduction of next-generation sequencing, diagnosed cases of patients with various causative gene variants are increasing.

5. Pathophysiology

Two categories of B cell dysfunction

The pathogenesis of hereditary hypogammaglobulinemia can be broadly divided into two categories. First, cases due to blockage of B cell development itself (early developmental defects) (BTK, IGHM deficiency, etc.), and second, cases in which B cell development is normal but there is reduced functional maturation and antibody secretion capacity (late differentiation defects) (NFKB1, LRBA, CTLA4 variants, etc.).

Role of the NF-κB signaling pathway

NF-κB signaling is essential for B cell survival, proliferation, and differentiation. With NFKB1 or NFKB2 variants, mature B cells are present, but final differentiation into antibody-secreting plasma cells and antibody production capacity are reduced. In this case, a hypogammaglobulinemia phenotype is seen rather than typical agammaglobulinemia.

LRBA deficiency and the CTLA-4 pathway

The LRBA protein regulates intracellular recycling of the CTLA-4 receptor. In LRBA deficiency, CTLA-4 is degraded, leading to overactivation of T cells and B cells and autoimmunity, accompanied paradoxically by immunodeficiency.

6. Symptoms

Infection-related symptoms

Recurrent bacterial infections (pneumonia, sinusitis, otitis media) are the main symptoms, and infection frequency and severity may be somewhat lower than in agammaglobulinemia. Chronic lung disease progressing to bronchiectasis is common. Patients are also vulnerable to herpesvirus and enterovirus infections.

Autoimmune complications

Autoimmune diseases frequently accompany hereditary hypogammaglobulinemia. Autoimmune thrombocytopenia, autoimmune hemolytic anemia, autoimmune neutropenia, inflammatory bowel disease, arthritis, and others may occur. Autoimmune complications are particularly prominent with LRBA, CTLA4, and CARD11 variants.

Lymphoproliferative complications

Some patients develop lymphadenopathy, splenomegaly, and granulomatous disease. The risk of lymphoma may be increased in hereditary hypogammaglobulinemia showing a CVID-like phenotype.

7. Signs

Physical examination findings

Unlike agammaglobulinemia, lymphadenopathy or splenomegaly may actually be observed. Bronchiectasis and chronic sinusitis due to recurrent infections are found. Pallor (anemia), petechiae (thrombocytopenia), and joint swelling due to autoimmune complications are sometimes observed.

Laboratory findings

Serum IgG is markedly lower than the lower limit of normal for age, and IgA and IgM are also decreased, but often not to completely undetectable levels. Peripheral blood B cell counts vary by cause and may be normal or decreased. Antigen-specific antibody responses (antibody production after vaccination) are reduced.

Imaging findings

Chest CT: bronchiectasis, pulmonary nodules (granulomas). Abdominal ultrasound/CT: splenomegaly, lymphadenopathy. Abnormal pituitary MRI findings are observed in some patients with NFKB2 variants.

8. Screening

Criteria for clinical suspicion

Immunodeficiency should be suspected in children or adults who have experienced recurrent bacterial infections, or in patients with autoimmune complications combined with susceptibility to infection. When there is a family history, screening of siblings and parents is recommended.

Quantification of serum immunoglobulins

Quantification of serum IgG, IgA, and IgM is the most basic and important screening test. When hypogammaglobulinemia below the age-based lower limit of normal is confirmed, further testing proceeds.

Measurement of functional antibodies

Functional antibody production capacity is evaluated by measuring specific antibody responses after vaccination (pneumococcal polysaccharide vaccine, tetanus vaccine). Failure of antibody response suggests functional hypogammaglobulinemia.

9. Diagnosis

Causative gene panel testing

After decreased serum immunoglobulins and lymphocyte subset abnormalities are confirmed, the causative variant is identified with an NGS panel (NFKB1, NFKB2, CARD11, LRBA, PIK3CD, PIK3R1, CTLA4, ICOS, BTK, etc.) including primary immunodeficiency causative genes.

Whole exome/genome analysis

When no cause is found by panel testing, new causative genes or atypical variants can be discovered through whole exome sequencing (WES) or whole genome sequencing (WGS).

Functional testing

To confirm the pathological significance of gene variants, functional tests such as T/B cell function tests, measurement of NF-κB activation, PI3K signaling analysis, and measurement of CTLA-4 surface expression are used as adjunctive diagnostics.

10. Treatment

Immunoglobulin replacement therapy

With recurrent infections or IgG < 5–6 g/L, IVIG or SCIG replacement therapy is started. The target is maintaining an IgG trough of 8 g/L or more, and the target is raised according to infection frequency and pulmonary complications.

Treatment of autoimmune complications

Immunosuppressive therapy (steroids, rituximab, mycophenolate) is given for autoimmune thrombocytopenia and hemolytic anemia. In LRBA deficiency, administration of CTLA-4 Ig (abatacept, belatacept) effectively improves autoimmunity and immune dysregulation. For PIK3CD gain-of-function variants, administration of PI3Kδ inhibitors (leniolisib, idelalisib) is under research and clinical application.

Hematopoietic stem cell transplantation

In LRBA deficiency, CARD11 loss of function, and some severe hereditary hypogammaglobulinemias, hematopoietic stem cell transplantation (HSCT) may be performed with the aim of cure. Transplantation is considered especially when autoimmune complications and immunodeficiency are severe.

11. Prognosis

Differences in prognosis by causative gene

Prognosis varies depending on the causative gene and clinical phenotype. In patients whose infections are well controlled with IgRT, a relatively normal quality of life can be maintained. Patients with LRBA deficiency, CTLA4 variants, or CARD11 loss of function with severe autoimmune complications need aggressive treatment such as immunosuppressive therapy and HSCT.

Long-term complications

Chronic lung disease (bronchiectasis), autoimmune organ damage, granulomatous disease, and lymphoma are the main factors determining long-term prognosis. Early detection and treatment of these complications through regular follow-up is important.

12. Prevention

Genetic counseling

Genetic counseling and carrier testing of family members are important. In autosomal dominant forms, one of the parents may be a carrier, so both sides of the family are tested. Prenatal diagnosis and preimplantation genetic testing (PGT-M) options are offered.

Infection prevention

Maintenance of regular IgRT, caution with live vaccines, early antibiotic treatment for infections, and regular monitoring of lung function are recommended.

Early detection of autoimmune complications

Autoimmune complications are detected early and treated through regular autoimmune marker tests, blood counts, and organ function assessment.

13. References

  1. Picard C, Bobby Gaspar H, Al-Herz W, et al. International Union of Immunological Societies: 2017 Primary Immunodeficiency Diseases Committee Report on Inborn Errors of Immunity. J Clin Immunol. 2018;38(1):96-128.
  2. Cunningham-Rundles C. The many faces of common variable immunodeficiency. Hematology Am Soc Hematol Educ Program. 2012;2012:301-305.
  3. Fliegauf M, Bryant VL, Frede N, et al. Haploinsufficiency of the NF-kappaB1 subunit p50 in common variable immunodeficiency. Am J Hum Genet. 2015;97(3):389-403.
  4. Grimbacher B, Hutloff A, Schlesier M, et al. Homozygous loss of ICOS is associated with adult-onset common variable immunodeficiency. Nat Immunol. 2003;4(3):261-268.
  5. Lo B, Zhang K, Lu W, et al. Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy. Science. 2015;349(6246):436-440.
  6. Angulo I, Vadas O, Garcon F, et al. Phosphoinositide 3-kinase delta gene mutation predisposes to respiratory infection and airway damage. Science. 2013;342(6160):866-871.
  7. Bonilla FA, Khan DA, Ballas ZK, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. J Allergy Clin Immunol. 2015;136(5):1186-1205.
  8. Notarangelo LD. Primary immunodeficiencies. J Allergy Clin Immunol. 2010;125(2 Suppl 2):S182-194.
  9. Ochs HD, Smith CIE, Puck JM. Primary Immunodeficiency Diseases: A Molecular and Genetic Approach. 3rd ed. Oxford University Press; 2013.
  10. Chapel H, Cunningham-Rundles C. Update in understanding common variable immunodeficiency disorders (CVIDs) and the management of patients with these conditions. Br J Haematol. 2009;145(6):709-727.
  11. Bogaert DJ, Dullaers M, Lambrecht BN, Vermaelen KY, De Baere E, Haerynck F. Genes associated with common variable immunodeficiency: one diagnosis to rule them all? J Med Genet. 2016;53(9):575-590.
  12. Seidel MG, Kindle G, Gathmann B, et al. The European Society for Immunodeficiencies (ESID) Registry Working Definitions for the Clinical Diagnosis of Inborn Errors of Immunity. J Allergy Clin Immunol Pract. 2019;7(6):1763-1770.